| Literature DB >> 31686769 |
Ravi Misra1, Jimmy Limdi2, Rachel Cooney3, Samia Sakuma4, Matthew Brookes5, Edward Fogden6, Sanjeev Pattni7, Naveen Sharma8, Tariq Iqbal3, Pia Munkholm9, Johan Burisch9, Naila Arebi4.
Abstract
BACKGROUND: The current epidemiology ofEntities:
Keywords: Epidemiology; Ethnicity; Incidence; Inflammatory bowel disease; Phenotype
Mesh:
Year: 2019 PMID: 31686769 PMCID: PMC6824277 DOI: 10.3748/wjg.v25.i40.6145
Source DB: PubMed Journal: World J Gastroenterol ISSN: 1007-9327 Impact factor: 5.742
Demographics of incident inflammatory bowel disease patients categorised by ethnicity
| Male sex, | 109 (53.2) | 42 (61.8) | 16 (66.7) | 25 (83.3) |
| Median age, yr (IQR range) | ||||
| CD | 35 (25-54) | 32 (29-35) | 29 (23-44) | 19 (16-27) |
| UC | 40 (28-59) | 38 (29-50) | 29 (23-37) | 34 (25-45) |
| Median time from symptom onset to diagnosis, mo (IQR) | ||||
| CD | 2.9 (0.9-8.5) | 3.0 (2.0-6.0) | 3.5 (2.0-5.3) | 3 (2.0-3.2) |
| UC | 2.3 (1.0-6.0) | 2.5 (0.98-4.0) | 2.7 (2.0-6.2) | 2.5 (1.7-3.4) |
| Smoking history, | ||||
| CD | ||||
| Never | 15 (22.0) | 3 (33.3) | 2 (40) | 3 (60) |
| Ex-smoker | 35 (51.4) | 3 (33.3) | 1 (20) | 1 (20) |
| Current | 18 (26.4) | 3 (33.3) | 2 (40) | 1 (20) |
| UC | ||||
| Never | 35c (38.0) | 28a (75.7) | 7b (77.8) | 17a (85.0) |
| Ex-smoker | 35 (38.0) | 7 (19.0) | 1 (11.1) | 2 (10.5) |
| Current | 22 (24.0) | 2 (5.4) | 1 (11.1) | 1 (5.3) |
| Born in the United Kingdom (%) | 91.2 | 85.2 | 66.6 | 89.9 |
| Family history of IBD, | 9 (5.7) | 4 (6.6) | 2 (11.1) | 1 (3.3) |
Significant difference in non-smoking (aP < 0.001) between Indian and White European; Significant difference in non-smoking (aP < 0.01) between Pakistani and White European; Significant difference in non-smoking. (cP < 0.001) between Other and White European. CD: Crohn’s disease; IBD: Inflammatory bowel disease; UC: Ulcerative colitis; IQR: Interquartile range.
Figure 2Ulcerative colitis incidence by ethnicity over adult age spectrum.
Figure 3Extent of ulcerative colitis at diagnosis across ethnic groups.
Figure 4Disease location and behaviour of Crohn’s disease by ethnic group.
Medical and surgical treatment within 3 mo of diagnosis by ethnic group
| UC | |||||
| None | 5 (4.6) | 3 (6.4) | 1 (7.7) | 2 (9.5) | 11 (5.8) |
| 5-ASA | 88 (81.5) | 42 (89.4) | 12 (92.3) | 12 (57.1) | 154 (81.4) |
| Steroids | 36 (33.3) | 16 (34.0) | 2 (15.4) | 4 (19.0) | 58 (30.7) |
| IM | 0 | 0 | 0 | 0 | 0 |
| Biologics | 7 (6.5) | 0 | 0 | 3 (14.3) | 10 (5.2) |
| Ciclosporin | 2 (1.9) | 0 | 0 | 0 | 2 (1.0) |
| Surgery | 2 (1.9) | 0 | 0 | 2 (9.5) | 4 (2.1) |
| CD | |||||
| None | 7 (8.5) | 2 (16.7) | 0 | 0 | 9 |
| 5-ASA | 31 (37.8) | 6 (50.0) | 2 (22.2) | 2 (28.6) | 43 |
| Steroids | 34 (41.5) | 6 (50.0) | 6 (66.7) | 4 (57.1) | 50 |
| IM | 19 (23.2) | 2 (16.7) | 4 (44.4) | 3 (42.9) | 28 |
| Biologics | 12 (14.6) | 0 | 1 (11.1) | 1 (14.3) | 14 |
| Other | 1 (1.2) | 0 | 0 | 0 | 1 |
| Surgery | 3 (3.7) | 0 | 0 | 0 | 3 |
IM: Immunomodulators; CD: Crohn’s disease; UC: Ulcerative colitis; 5-ASA: 5-aminosalicylic acid.